| 초록 |
Background: Kidney transplatation (KT) is a gold standard for treatment of end-stage kidney disease. Here, we report the clinical outcomes of KT recipients who reside at relatively short distance from our center.
Methods: We retrospectively reviewed 301 patients (127 of female sex) who underwent KT (140 from deceased donor, 161 from living donor) at Ulsan University Hospital from July 1998 to May 2015.
Results: Median follow-up was 48 months. Mean age of recipients and donors are 43.8 and 43.4 years, respectively. Pannel reactive antigen test was positive for 42 and was negative for 152 patients. Nine patients have a history of previous kidney transplantation and 9 KTs were ABO incompatile. Basiliximab and thymoglobulin were used for induction for 251 and 15 patients, respectively. Tacrolimus was initial calcineurin inhibitor for 243 KTs. Biopsy-proven acute rejection (BPAR) occurred to 56 patiens (40 of acute cellular rejection, 5 of antibody-mediated rejction, 4 of mixed and 7 of undifferentiated). BPAR-free survival was 89.7% at 1 year and 80.9% at 5 year. Malignancy and new-onset diabetes after KT developed for 10 and 43 recipients, respectively. During follow-up, 13 grafts were lost and 5- and 10-year death-censored graft survival was 97.2% and 91.2% respectively. Among 9 ABO incompatible KTs, no graft was lost during 7 - 53 months after transplantation (median 29 months). Seven patients died, and 5- and 10-year patient survival was 98.5% and 93.7%, respectively.
Conclusion: We experienced favorable clinical outcomes of KT recipients who reside close range from our center.
Table: Outcomes of kidney recipients |